Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PPB-R-203
- Development stage
- Preclinical
- Lead developer
- Pharma Power Biotec
- Administration
- Oral
01
Overview
PPB-R-203 is a resistant starch (RS)-based dietary formulation developed to reduce postprandial hyperglycemia in patients with type 2 diabetes. It functions primarily by slowing the digestion and absorption of carbohydrates, thereby lowering blood glucose excursions after meals. The active carbohydrate composition is approximately 10% degraded starch, 20% amylase, and 70% amylopectin. Mechanistically, RS may regulate glucose metabolism via fermentation by colonic microbiota to produce short-chain fatty acids as well as possible bile acid modulation[1][8][10].
- Brand names
- PPB-R-203PPB-R203PPB-R 203
- Other names
- PPB-R-203PPB-R203PPB-R 203
Beyond the preview
Go deeper on PPB-R-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PPB-R-203.